Kumar Neil: insider trades.
Kumar Neil reported 14 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 9 sales ($4.4M), across 1 company.
- Transactions
- 14
- Purchases (P)
- 0
- Sales (S)
- 9
- Companies
- 1
- Name as filed
- Kumar Neil
Companies
| Company | Relationship | Transactions |
|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | Director, Officer · Chief Executive Officer | 14 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-17 | BridgeBio Pharma, Inc. | S | 1,279 | $69.57 | 495,686 | Form 4 |
| 2026-09-17 | BridgeBio Pharma, Inc. | S | 8,721 | $69.01 | 496,965 | Form 4 |
| 2026-08-19 | BridgeBio Pharma, Inc. | S | 100 | $85.65 | 505,686 | Form 4 |
| 2026-08-19 | BridgeBio Pharma, Inc. | S | 1,800 | $84.69 | 505,786 | Form 4 |
| 2026-08-19 | BridgeBio Pharma, Inc. | S | 8,100 | $83.86 | 507,586 | Form 4 |
| 2026-08-18 | BridgeBio Pharma, Inc. | S | 14,602 | $82.99 | 244,526 | Form 4 |
| 2026-08-18 | BridgeBio Pharma, Inc. | S | 1,900 | $81.15 | 276,407 | Form 4 |
| 2026-08-18 | BridgeBio Pharma, Inc. | S | 17,279 | $82.21 | 259,128 | Form 4 |
| 2026-08-18 | BridgeBio Pharma, Inc. | S | 1,199 | $83.77 | 243,327 | Form 4 |
| 2026-08-16 | BridgeBio Pharma, Inc. | F | 36,237 | $79.86 | 278,307 | Form 4 |
| 2026-08-16 | BridgeBio Pharma, Inc. | M | 6,520 | — | 314,544 | Form 4 |
| 2026-08-16 | BridgeBio Pharma, Inc. | M | 19,599 | — | 296,470 | Form 4 |
| 2026-08-16 | BridgeBio Pharma, Inc. | M | 33,544 | — | 276,871 | Form 4 |
| 2026-08-16 | BridgeBio Pharma, Inc. | M | 11,554 | — | 308,024 | Form 4 |
Questions
What stock did Kumar Neil buy or sell?
Kumar Neil reported 14 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 9 sales ($4.4M), across 1 company.
Is Kumar Neil the same person as other filers with this name?
This page covers SEC CIK 1742485 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/kumar-neil-1742485.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.